Objective. To identify factors influencing the results of medical technology assessment.

Materials and methods. This analysis is based on previously performed clinical (pharmaco) economic studies in the Republic of Belarus during ten years. The primary data analysis methods for inclusion in this publication have been cost-of-disease analysis, cost / effectiveness analysis, cost /utility analysis. All costs are presented in US dollars based on exchange rates at the time of realisation. Ranges are presented as maximum and minimum values.

Results. Influence analysis of the stage of the disease, conditions of medical care, the form of release for drugs, the age of the target population for the use of MT, the source of information on the price of technology on the results of the medical technology assessment has been performed. Evaluation of the ratio of the results of the cost of disease analysis for the implementation of the clinical protocol and the capabilities of the healthcare system (stable angina pectoris, type 2 diabetes mellitus), as well as for a number of special medical technologies (hemophilia A; post-stroke spasticity; mantle cell lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, lung cancer) is carried out.

Conclusion. It can be concluded that there is a need for clear formulations of goals and objectives at the stage of formation of the study design, taking into account the influence of the position of the researcher, the source of information on the price of MT, the selected population, the form of release (for drugs), conditions of medical care on the main clinical and economic indicators and on the subsequent interpretation of the results of HTA.